Plateau levels of hF.IX transgene expression and anti-hF.IX antibody formation at week 27
| Animal no. . | IS regimen . | hF.IX, ng/mL . | hF.IX, % of normal . | Anti-hF.IX IgG, ng/mL . | Bethesda titer, BU . |
|---|---|---|---|---|---|
| 1001 | None | 479 | 9.6 | 2000 | 0 |
| 1002 | None | 200 | 4.0 | 2500 | 0 |
| 1003 | None | 188 | 3.8 | 2300 | 0 |
| 2001 | MMF, sirolimus, daclizumab | 0 | 0 | 14172 | 1.1 |
| 2002 | MMF, sirolimus, daclizumab | 0 | 0 | 32224 | 215 |
| 2003 | MMF, sirolimus, daclizumab | 0 | 0 | 22027 | 45 |
| 3001 | MMF, sirolimus | 365 | 7.3 | 428 | 0 |
| 3002 | MMF, sirolimus | 242 | 4.8 | 2923 | 0 |
| 3003 | MMF, sirolimus | 240 | 4.8 | 8588 | 0 |
| Animal no. . | IS regimen . | hF.IX, ng/mL . | hF.IX, % of normal . | Anti-hF.IX IgG, ng/mL . | Bethesda titer, BU . |
|---|---|---|---|---|---|
| 1001 | None | 479 | 9.6 | 2000 | 0 |
| 1002 | None | 200 | 4.0 | 2500 | 0 |
| 1003 | None | 188 | 3.8 | 2300 | 0 |
| 2001 | MMF, sirolimus, daclizumab | 0 | 0 | 14172 | 1.1 |
| 2002 | MMF, sirolimus, daclizumab | 0 | 0 | 32224 | 215 |
| 2003 | MMF, sirolimus, daclizumab | 0 | 0 | 22027 | 45 |
| 3001 | MMF, sirolimus | 365 | 7.3 | 428 | 0 |
| 3002 | MMF, sirolimus | 242 | 4.8 | 2923 | 0 |
| 3003 | MMF, sirolimus | 240 | 4.8 | 8588 | 0 |